Overview

Phase I Comparative Bioavailability Study

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Olaparib